# The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine

> **NCT03698331** · PHASE4 · COMPLETED · sponsor: **Neurocrine Biosciences** · enrollment: 89 (actual)

## Conditions studied

- Tardive Dyskinesia (TD)

## Interventions

- **DRUG:** Valbenazine
- **DRUG:** Placebo oral capsule

## Key facts

- **NCT ID:** NCT03698331
- **Lead sponsor:** Neurocrine Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-14
- **Primary completion:** 2019-04-03
- **Final completion:** 2019-04-03
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2020-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03698331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03698331, "The Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03698331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*